Faron Pharmaceuticals Oy
Research Faron Pharmaceuticals Oy (FARON) on Bullrun: market cap EUR 94.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFARON
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 94.44M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 27.26M
- Free cash flow-EUR 18.14M
Valuation Snapshot
latest market cap is EUR 94.44M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 27.26M | -EUR 18.14M | n/a | n/a | EUR 12.32M | EUR 24.68M | -EUR 18.51M |
| FY2024 | EUR 0 | -EUR 25.92M | -EUR 22.53M | n/a | -0.27 | EUR 9.50M | EUR 12.11M | -EUR 9.76M |
| FY2023 | EUR 0 | -EUR 30.94M | -EUR 23.93M | n/a | -0.37 | EUR 6.88M | EUR 13.11M | -EUR 15.16M |
| FY2022 | EUR 0 | -EUR 28.73M | -EUR 23.38M | n/a | -0.4 | EUR 6.99M | EUR 13.27M | -EUR 11.48M |
| FY2021 | n/a | n/a | n/a | n/a | -0.32 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 94.44M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Faron Pharmaceuticals Oy's market cap?
Faron Pharmaceuticals Oy's market capitalization is EUR 94.44M.
What does Faron Pharmaceuticals Oy do?
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.